Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis

Elgendy et al. show that metformin administered during the fasting period synergizes with 24-h feeding/fasting cycles to suppress tumor growth. Inhibition of CIP2A by metformin and upregulation of B56δ by low glucose activates PP2A toward GSK3β leading to reduced pro-survival protein MCL-1 and cell death.

from Cancer Cell http://bit.ly/2vn63EU